TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Adolescent Drug Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Subjective Nasal Scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analytical accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in faces pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinical toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: changes in a peripheral blood biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Feasibility of continuous bronchoscopy during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PCIA duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting Solicited Injection Site or Systemic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titers Ratios of Influenza Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Seroconversion or Significant Increase in Influenza Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Volumetric buccal bone changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondrial activity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAO incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression Scale (CGI) - Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Aberrant Behavior Checklist (ABC)
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Vineland Adaptive Behavior Scale
Endpoint domain: Life impact
Endpoint subdomain: Adaptive functioning
Primary endpoint: Time to First Use of Rescue Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major adverse cardio-cerebral events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful Replacements of Dislodged PEG Tubes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of ASP2151
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Peak Concentration (Tmax) of ASP2151
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of ASP2151
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in wheelchair usage per day (time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in wheelchair usage per day (distance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in activity level of patient reported wheelchair use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in viral loads of human papillomaviruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in viral loads of cytomegalovirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in viral loads of Epstein-Barr virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent change in total hip BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Percent change in lumbar spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Intrapulmonary shunt ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: total number of circulating fibrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Substance Use Occasions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fundamental frequency (f0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Complete Detoxification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful version of the fetus into the vertex position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Blood culture obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Increased serum sodium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental shuttle walk test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regulatory T-Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Savolitinib area under plasma concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Savolitinib maximum observed plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects with seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fold increase in geometric mean titer (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in urine protein creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change rate in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients returning for visits
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Sensitivity of OGM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of OGM with standard of care testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of OGM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Left Ventricular Remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coagulation profile derangement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Haematopoietic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline to Week 182 in Percent Predicted Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline to Week 182 in Six Minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Rating on the Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intensity of HAV symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy expenditure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjective appetite feelings change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetic profiles of ASA404 and metabolites in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetic profiles of total radioactivity in blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Probability of Progression-free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Improved Response Rate After Treatment With 131I-tositumomab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Minimal Residual Disease (MRD) by Flow Cytometry or PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Memory and Attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Level of glycosylated hemoglobin (HbA1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Albumin/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to Resolution of All Clinical Symptoms of Influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Early detection of life threatening changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Over Time on Salivary Cortisol Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: skin elasticity parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in penile curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder in Disability Assessment Scale (DAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in airway hyper-responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hernia Recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Surgical Site Infection Requiring Wound Opening
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of rapid test compared to ELISA test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of rapid test compared to ELISA test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABC Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: actual weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful retrieval of reflector
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful retrieval of biopsied node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reported level of normative body image
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discrepancy between perceived body image and preferred body image
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of Life as measured by QOL-AD
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sedative use
Endpoint domain: Adverse events/effects
Primary endpoint: Measurement of stenosis percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC0-tlast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treadmill Walking Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure medication adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Therapeutic Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Successfully Able to Self-administer Doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of BB-12 yogurt
Endpoint domain: Adverse events/effects
Primary endpoint: Peak % of Baseline Eosinophil Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number consenting to join study out of eligible patients approached
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of times therapists adhered to prescribed therapeutic protocol
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in lung function (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Eligibility of patients with CNS tumors for research protocols
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of dreaming
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Transition readiness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Retention in adult care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Horizontal clinical attachment level (HCAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appetitive aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Current violent behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saliva insulin area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Saliva insulin at different time points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Annual incidence of MTC
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGF1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Reach TOF Ratio ≥ 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TOF Ratio at 90 Min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Very Good Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient agreement on doctor discussion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Liver function tests values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lamotrigine AUC(0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lamotrigine Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cord-disease Distance of at Least 3mm After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Demonstrating Successful Radiographic Response of the Spinal Tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight in kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood fasting glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Units of Packed Red Blood Cell Transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Transfused Patients in Each Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peripheral oxygen saturation (SpO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Number of Daily Episodes of Urinary Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Adverse Events Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mean Daily Steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Severe Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinued From the Study Due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) by Cardiac MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of participants who use any of the proposed contraceptive methods
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of participants who adhere to the use of the proposed contraceptive methods
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Thoraco-abdominal activity of the muscular walls
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants who engage in depression treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in PHQ-9 (depressive symptoms) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain during isometric contraction of the ECRB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 2 Year Disease-Free Survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Markers of cardiometabolic risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body composition as measured by DEXA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life as measured by PedsQL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Change in Functional Capacity (Peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of cholangiopathic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of peptic ulcer disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Stable or Improved Forced Vital Capacity (FVC) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response to intermittent photic stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with stable CAD appropriate for PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delta AUCBG,0-2h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of clotting in the extracorporeal circuit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of CMV Specific T cell infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to non-invasive ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total antibiotic use during hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occurrence of radiodermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in receipt of a Pap test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Viral failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in expression levels of platelet messenger RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in MPS index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in modified Oral Health Impact Profile (OHIP14)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical Global Impression Scale-Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score on depression and mania rating scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Working activity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Blood THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine THC-COOH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Fluid THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective rating of Drug Effect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptoms in Breast Cancer-Related Lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Compliance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Activity Levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Level of objective understanding of CKD
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Level of perceived understanding of CKD
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Transfusion-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability based on expected dose compliance
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline on Addenbrooke's Cognitive Examination - Revised (ACE-R)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline on Functional Activities Questionnaire (FAQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning